Senetek Launches Pyratine-6(TM)

Thursday, September 4, 2008 General News J E 4
NAPA, Calif., Sept. 4 Senetek PLC(OTC Bulletin Board: SNKTY), a life sciences company engaged in thedevelopment of technologies that target the science of healthy aging,announced today the launch of Pyratine-6(TM), representing the next generationof superior skincare products for the correction of visible signs of aging.In the 1990's Senetek developed kinetin, the cytokinin-based active ingredientin the successful Kinerase skincare line, and are now taking cytokinintechnology further with Pyratine-6(TM).

Pyratine-6(TM)'s new cytokinin technology works faster than kinetin or anyother product on the market in dramatically reducing roughness and rednessstarting in as little as two weeks, with full results on fine wrinkles,dryness, discoloration, and other signs of photodamage in twelve weeks ofconsistent use. Clinical studies showed improvement in pre-existing rednessassociated with rosacea, eczema, contact dermatitis and menopause.

Cytokinins are natural plant-derived growth factors that stimulate growthand differentiation. While they do not stimulate proliferation of humancells, cytokinins have proved to be superior anti-aging agents in skin cells.By functioning as antioxidants, they purge cellular debris and delay the agingprocess. The enhanced Pyratine-6(TM) cytokinin is the most effective andfastest acting cytokinin available today.

In a clinical study of 34 patients, Pyratine-6(TM) was well tolerated by33 of the patients. Because it is non-acidic and without irritants,Pyratine-6(TM) shows 0 on a 4-point scale of irritation and can be used inconjunction with treatment procedures such as chemical peels, laserresurfacing, microdermabrasion and injectables. It has no know interactionswith drugs or other products and, it can be used before the application ofcosmetics and in conjunction with sunscreen and other enhancement products.

In an independent study by Dr. Jerry L. McCullough from the University ofCalifornia, Irvine, et al published in the February 2008 Journal of Drugs inDermatology, Dr. McCullough stated, "Treatment with Pyratine-6(TM) (0.1%) over12 weeks improves roughness and skin moisturization in 2 weeks andhyperpigmentation and fine wrinkles in 4 weeks." Further, the report statedthat adverse effects of Pyratine-6(TM) are "minimal" and "transient."

Pyratine-6(TM) will be available starting in September 2008 only throughdermatologists, plastic surgeons and top medical spas across the country,providing its high efficacy and specialized benefits in a professionalenvironment. For a list of physicians and medical spas carryingPyratine-6(TM) call 888-GO-PYRATINE or 877-586-3747.

About Senetek, PLC

Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in thedevelopment of breakthrough technologies that target the science of healthyaging. The company's extensive research collaborations have resulted in astrong pipeline of patented compounds and products with broad therapeuticapplications and a leading presence in dermatology. Senetek collaborates withestablished specialty pharmaceutical companies in the final development andmarketing of its proprietary products, most recently resulting in thedevelopment of kinetin, the best-selling anti-aging product sold in the NorthAmerican physician market. For more information, visit the company's websiteat



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Your Baby's First Genetic Test: Five Questions for...
S Issues Technical Trade Alerts on ...